Clinical benefits of pegylated proteins in oncology

Cancer Treatment Reviews

Volumn 28, Issue SUPPL. A, 2002, Pages 1-2

  Crawford, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; MACROGOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; EDITORIAL; HUMAN; IMMUNOGENICITY; KAPOSI SARCOMA; NEUTROPENIA; QUALITY OF LIFE;

EID: 0036086448     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2002.0251     Document Type: Article

References (7)

1. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
2. Polyethylene glycol conjugated pharmaceutical proteins
3. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy
4. Phase II trial of branched pegylated (40kDa) interferon α-2a for patients with advanced renal cell carcinoma (RCC)
5. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
6. Improvements in protein PEGy-lation: Pegylated interferons for treatment of hepatitis C
7. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma